Butamyrate + Guaifenesin (Butamiratum + Guaiphenesinum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antitussives

Included in the formulation
  • Stopoutsin
    drops inwards 
    Teva Pharmaceutical Enterprises Co., Ltd.     Israel
    • АТХ:

    R.05.F.B.02   Antitussive drugs in combination with expectorants

    Pharmacodynamics:

    Blockade of cough reflex at the level of the cough center. Combined drug, has antitussive and expectorant (secretolitic) effect. Butamirate citrate also has a local anesthetic effect on bronchial receptors, providing antitussive and bronchodilator effects.

    Guaifenesin increases the secretion of bronchial glands and reduces the viscosity of phlegm. The increase in secretion is caused both by direct action on the bronchial glands, by stimulation of secretion from the bronchial glands and removal of acidic glycoproteins from acinar cells, and by reflexes, when the afferent parasympathetic fibers of the gastric mucosa irritate and the respiratory center is depressed. Increased n tone. vagus stimulates the production of bronchial secretions. Sputum produced by the bronchial glands enhances the activity of the ciliated epithelium, thereby facilitating the evacuation of sputum from the bronchi and its coughing.

    Pharmacokinetics:

    When administered butramate citrate quickly and completely absorbed. The connection with plasma proteins is 94%.It is metabolized with the formation of two metabolites, which also have antitussive action. Metabolites are excreted mainly by the kidneys (90%) and only a small part through the intestines. Half-life is 6 hours.

    Guaifenesin is rapidly absorbed from the gastrointestinal tract when ingested. The connection with plasma proteins is insignificant. Guaifenesin rapidly metabolized, with the formation of inactive metabolites, which are excreted by the kidneys. Half-life is 1 hour.

    Indications:Dry cough and irritating cough of various etiologies (including with infectious inflammationAlzheimer's diseases of the upper and lower respiratory tract).
    ICD-10

    X.J00-J06.J04   Acute laryngitis and tracheitis

    X.J20-J22.J20   Acute bronchitis

    X.J00-J06.J06.8   Other acute upper respiratory tract infections of multiple localization

    X.J20-J22.J22   Acute respiratory infection of lower respiratory tract, unspecified

    XVIII.R00-R09.R05   Cough

    Contraindications:Hypersensitivitypregnancy, I trimester, lactation, children under 6 months (for drops), up to 12 years (for depot tablets).
    Carefully:Diseases accompanied by productive cough; arterial hypertension.
    Pregnancy and lactation:

    Category of recommendations Food and Drug Administration (US Food and Drug Administration) not determined.

    Butamirate is contraindicated for use in the first trimester of pregnancy and during lactation (breastfeeding). In the II and III trimesters of pregnancy butamate and guaifenesin use with caution, only in those cases where the expected therapeutic effect for the mother exceeds the potential risk to the fetus.

    Dosing and Administration:

    The drug is taken orally after a meal. Tablets take whole, not liquid, squeezed liquid (water, tea, fruit juice).

    Adults and children over 12 years of age the drug is dosed depending on the patient's body weight: less than 50 kg - 1/2 tablet 4 times a day; 50-70 kg - 1 tablet 3 times a day; 70-90 kg - 1,5 tablets 3 times a day; more than 90 kg - 1,5 tablets 4 times a day.

    The interval between doses should be 4-6 hours.

    Drops: the appropriate number of drops are dissolved in 100 ml of liquid (water, tea, fruit juice).

    Dosage depending on the patient's body weight: less than 7 kg - 8 drops 3-4 times a day; 7-12 kg - 9 drops 3-4 times a day; 12-20 kg - 14 drops 3 times a day; 20-30 kg - 14 drops 3-4 times a day; 30-40 kg - 16 drops 3-4 times a day; 40-50 kg - 25 drops 3 times a day; 50-70 kg - 30 eachdrops 3 times a day; - more than 70 kg of 40 drops 3 times a day.

    The interval between doses should be 6-8 hours.

    The use of a large amount of fluid during the course of treatment enhances its effectiveness. When used in children weighing less than 7 kg, a dose reduction is possible because the child does not drink all 100 ml of the prepared mixture, however, the total concentration of the preparation should not be exceeded.

    Side effects:

    From the digestive system: nausea, vomiting, diarrhea, pain in the stomach.

    From the nervous system: headache, drowsiness.

    From the side of the organ of hearing and balance: dizziness.

    From the digestive system: nausea, anorexia, abdominal pain, decreased appetite, vomiting, diarrhea; very rarely - a bitter taste in the mouth, heartburn, a feeling of heaviness in the epigastrium.

    From the respiratory system: very rarely - dyspnea.

    From the cardiovascular system: rarely chest pain; very rarely - tachycardia, palpitation.

    From the skin and subcutaneous fat: itching, exanthema, urticaria.

    Other: very rarely - hot flashes, pain around the eyes, muscular weakness, urolithiasis.

    Overdose:

    Symptoms: drowsiness, nausea, vomiting, abdominal pain, diarrhea, dizziness, irritability, impaired coordination of movements, muscle weakness, lowering blood pressure, urolithiasis.

    Treatment: In case of overdose, see a doctor. Guaifenesin does not have a specific antidote. Assign gastric lavage, reception of activated charcoal, symptomatic therapy (support of cardiovascular, respiratory and renal functions, electrolyte balance).

    Interaction:Guaifenesin enhances the analgesic effect of paracetamol and acetylsalicylic acidth acid, the effect of alcohol, sedatives, hypnotics and general anesthetics on the central nervous system, the action of muscle relaxants.
    Special instructions:

    During the period of treatment is not recommended to drink alcohol and drugs that suppress the central nervous system (hypnotics, neuroleptics, tranquilizers and others.).

    The drug should not be administered with productive cough to patients suffering from prolonged or chronic cough (including caused by smoking), bronchitis or emphysema of the lungs.

    Impact on the ability to drive vehicles and manage mechanisms

    It can have an adverse effect on the ability to drive vehicles and to engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions, due to the fact that it can cause dizziness and other side effects.

    Instructions
    Up